An interventional study of Up-front individualized dosing algorithm and Usual Care in Sepsis and Infection, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Sepsis by Mayo Clinic — 2 open to participants now, 4 under way, none of them phase 3. Sepsis · Mayo Clinic.
Among the 16 studies in Sepsis by Mayo Clinic, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is one of 6 with no phase, and was the 16th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →2 of the 16 studies in Sepsis by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 102 across 1,169 interventional studies indexed under Sepsis.
Median enrollment 354 across the 10 interventional studies, 258 across the 6 observational. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
3 of the studies in Sepsis by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06817408Mayo ClinicDynamics of Organ Damage and Immune Exhaustion During Sepsis | 2026-12 |
| NCT06905080Mayo ClinicDialysis Catheter Caps Case Feasibility Study | 2026-12-31 |
| NCT07287332Mayo ClinicBLOOM: Pragmatic Feasibility Trial | 2027-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Sepsis by Mayo Clinic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study is to compare two different ways of dosing cefepime, an antibiotic for very sick patients - the usual approach to dosing or a new dosing method. The new dosing method uses only doses that are available in normal care, but choosing between the different doses is based on more information about the patient's body including their kidney function. The primary purpose of this study is to test how easy it is for healthcare professionals to use the new dosing method and how best to conduct the trial. The study will also assess if the new dosing method helps patients recover faster and reduces side effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Clinical decision support to encourage use of an individualized cefepime dosing algorithm based on eGFRcr-cysC and weight.
Other: Up-front individualized dosing algorithm
The standard of care group will receive empiric dosing of cefepime, using an institutional antimicrobial guide based on four categories of eGFRcr.
Other: Usual Care
An individualized cefepime dosing algorithm will be used to determine the cefepime dose and interval. The dose recommendation will be provided using the EHR-prompts to the clinical care team and ordered and/or verified by the ICU pharmacist using an established collaborative practice agreement. As a pragmatic trial, at any point care teams may modify the empiric or subsequent dose based on their clinical judgement.
The standard of care group will receive empiric dosing guided by an institutional antimicrobial guide. Cefepime is typically dosed at 0.5-2 g every 8-24 h according to categorical thresholds of estimated creatinine clearance (eGFRcr). Cystatin C and eGFRcr-cys can be calculated and used at clinicians' discretion to aid in drug dose determination.
Proportion of patients screened who qualified for the study
Number of patients who quality for the study out of total number of patients screened, reported as a percentage
Time frame: 1 year or once the sample size is achieved
Distribution of qualified patients across care teams
Number of patients from each ICU care team who qualify for the study
Time frame: 1 year or once the sample size is achieved
Adherence to dosing recommendations
Total number of patients randomized to the up-front individualized dosing algorithm who are prescribed the algorithm's recommended dosage
Time frame: 1 year or once the sample size is achieved
Number of antibiotic-free days
Number of antibiotic-free days for the first 28 days
Time frame: 28-days
ICU length of stay
Number of days of initial ICU stay
Time frame: 1 year
Proportion of patients who experience new anti-Pseudomonal beta-lactam resistance
New anti-Pseudomonal beta-lactam resistance which develops within the 6 months following initial treatment
Time frame: 6 months
Proportion of patients who experience clinical success
Complete or partial resolution of clinical signs and symptoms attributed to infection across 8 days of therapy.
Time frame: 8 days
Proportion of patients who experience microbiologic success
Presumed or documented eradication of causative microorganisms
Time frame: 8 days
Mortality
All cause death
Time frame: 28-days
Plan to share: No
Started Jan 2026 (actual). Primary completion is estimated for Mar 2027, 14 months after the start.
Of 303 non-industry interventional studies with no phase under Sepsis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 14 months is below that.
Counting every sponsor, half of 326 studies reached it within 22 months; a quarter within 11 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.